Institute of Developmental Biology and Regenerative Medicine, Southwest University, Beibei, Chongqing, 400715, China.
Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Proteos, 61 Biopolis Drive, Singapore, 138673, Singapore; Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, Singapore, 119288, Singapore; Department of Biological Sciences, National University of Singapore, 14 Science Drive 4, Singapore, 117543, Singapore.
Trends Mol Med. 2023 Apr;29(4):268-281. doi: 10.1016/j.molmed.2023.01.005. Epub 2023 Feb 15.
Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening monogenic disease caused by mutations in PKD1 and PKD2 that encode polycystin 1 (PC1) and polycystin 2 (PC2). PC1/2 localize to cilia of renal epithelial cells, and their function is believed to embody an inhibitory activity that suppresses the cilia-dependent cyst activation (CDCA) signal. Consequently, PC deficiency results in activation of CDCA and stimulates cyst growth. Recently, re-expression of PCs in established cysts has been shown to reverse PKD. Thus, the mode of action of PCs resembles a 'counterbalance in cruise control' to maintain lumen diameter within a designated range. Herein we review recent studies that point to novel arenas for future PC research with therapeutic potential for ADPKD.
常染色体显性多囊肾病 (ADPKD) 是一种危及生命的单基因疾病,由 PKD1 和 PKD2 基因突变引起,这些基因编码多囊蛋白 1 (PC1) 和多囊蛋白 2 (PC2)。PC1/2 定位于肾上皮细胞的纤毛,其功能被认为体现了一种抑制活性,抑制纤毛依赖性囊肿激活 (CDCA) 信号。因此,PC 缺乏会导致 CDCA 的激活,并刺激囊肿生长。最近的研究表明,在已建立的囊肿中重新表达 PCs 可逆转 PKD。因此,PC 的作用模式类似于“巡航控制中的平衡抵消”,以将管腔直径维持在指定范围内。本文综述了最近的研究,这些研究指出了具有 ADPKD 治疗潜力的新型 PC 研究领域。